Skip to main content
Erschienen in: HNO 5/2018

23.04.2018 | Erkrankungen von Nase, Nebenhöhlen und Gesicht | CME

Diagnostik und Therapie des M. Osler

verfasst von: PD Dr. med. F. Haubner, Prof. Dr. T. Kühnel

Erschienen in: HNO | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Der M. Osler stellt eine autosomal-dominante seltene Erberkrankung dar. Die Betroffenen leiden v. a. unter der Epistaxis. Die Diagnosestellung beruht auf den Curaçao-Kriterien und der Gendiagnostik. Organmanifestationen finden sich als arteriovenöse Shunts im Bereich von Lunge, Leber, Gastrointestinaltrakt, seltener im Zentralnervensystem (ZNS) und anderen Körperregionen. Viele Patienten mit gastrointestinalen und anderen Organmanifestationen sind häufig klinisch asymptomatisch. Das Organscreening ist von elementarer Bedeutung zur Vermeidung von Komplikationen und sollte an Zentren mit besonderer Expertise durchgeführt werden. Derzeit existiert keine kausale Therapieoption. Von HNO-ärztlicher Seite stellt die nasale Schleimhautpflege sowie die endonasale Lasertherapie eine wichtige Säule in der Behandlung der Epistaxis dar. Medikamentöse Therapieansätze zielen auf die Kompensation der Haploinsuffizienz sowie Antiangiogenese ab und sind z. T. mit schwerwiegenden Nebenwirkungen assoziiert.
Literatur
1.
Zurück zum Zitat Sutton HG (1864) Epistaxis as an indication of impaired nutrition, and of degeneration of the vascular system. Med Mirror 1:769–781 Sutton HG (1864) Epistaxis as an indication of impaired nutrition, and of degeneration of the vascular system. Med Mirror 1:769–781
2.
Zurück zum Zitat Faughnan ME et al (2011) International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 48(2):73–87CrossRefPubMed Faughnan ME et al (2011) International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 48(2):73–87CrossRefPubMed
3.
Zurück zum Zitat Braverman IM, Keh A, Jacobson BS (1990) Ultrastructure and three-dimensional organization of the telangiectases of hereditary hemorrhagic telangiectasia. J Invest Dermatol 95(4):422–427CrossRefPubMed Braverman IM, Keh A, Jacobson BS (1990) Ultrastructure and three-dimensional organization of the telangiectases of hereditary hemorrhagic telangiectasia. J Invest Dermatol 95(4):422–427CrossRefPubMed
4.
Zurück zum Zitat Shovlin CL (2010) Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 24(6):203–219CrossRefPubMed Shovlin CL (2010) Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 24(6):203–219CrossRefPubMed
6.
Zurück zum Zitat Santibanez JF, Quintanilla M, Bernabeu C (2011) TGF-beta/TGF-beta receptor system and its role in physiological and pathological conditions. Clin Sci 121(6):233–251CrossRefPubMed Santibanez JF, Quintanilla M, Bernabeu C (2011) TGF-beta/TGF-beta receptor system and its role in physiological and pathological conditions. Clin Sci 121(6):233–251CrossRefPubMed
7.
Zurück zum Zitat Abdalla SA, Letarte M (2006) Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J Med Genet 43(2):97–110CrossRefPubMedPubMedCentral Abdalla SA, Letarte M (2006) Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J Med Genet 43(2):97–110CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Gallione C et al (2010) Overlapping spectra of SMAD4 mutations in juvenile polyposis (JP) and JP-HHT syndrome. Am J Med Genet A 152A(2):333–339CrossRefPubMed Gallione C et al (2010) Overlapping spectra of SMAD4 mutations in juvenile polyposis (JP) and JP-HHT syndrome. Am J Med Genet A 152A(2):333–339CrossRefPubMed
9.
Zurück zum Zitat Wooderchak-Donahue WL et al (2013) BMP9 mutations cause a vascular-anomaly syndrome with phenotypic overlap with hereditary hemorrhagic telangiectasia. Am J Hum Genet 93(3):530–537CrossRefPubMedPubMedCentral Wooderchak-Donahue WL et al (2013) BMP9 mutations cause a vascular-anomaly syndrome with phenotypic overlap with hereditary hemorrhagic telangiectasia. Am J Hum Genet 93(3):530–537CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Kawasaki K et al (2014) Genetic variants of Adam17 differentially regulate TGFbeta signaling to modify vascular pathology in mice and humans. Proc Natl Acad Sci USA 111(21):7723–7728CrossRefPubMedPubMedCentral Kawasaki K et al (2014) Genetic variants of Adam17 differentially regulate TGFbeta signaling to modify vascular pathology in mice and humans. Proc Natl Acad Sci USA 111(21):7723–7728CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Tual-Chalot S, Oh SP, Arthur HM (2015) Mouse models of hereditary hemorrhagic telangiectasia: recent advances and future challenges. Front Genet 6:25CrossRefPubMedPubMedCentral Tual-Chalot S, Oh SP, Arthur HM (2015) Mouse models of hereditary hemorrhagic telangiectasia: recent advances and future challenges. Front Genet 6:25CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Mahmoud M et al (2010) Pathogenesis of arteriovenous malformations in the absence of endoglin. Circ Res 106(8):1425–1433CrossRefPubMed Mahmoud M et al (2010) Pathogenesis of arteriovenous malformations in the absence of endoglin. Circ Res 106(8):1425–1433CrossRefPubMed
13.
Zurück zum Zitat Gluckman JL, Portugal LG (1994) Modified Young’s procedure for refractory epistaxis due to hereditary hemorrhagic telangiectasia. Laryngoscope 104(9):1174–1177CrossRefPubMed Gluckman JL, Portugal LG (1994) Modified Young’s procedure for refractory epistaxis due to hereditary hemorrhagic telangiectasia. Laryngoscope 104(9):1174–1177CrossRefPubMed
14.
Zurück zum Zitat Garrido-Martin EM et al (2013) Vascular injury triggers Kruppel-like factor 6 mobilization and cooperation with specificity protein 1 to promote endothelial activation through upregulation of the activin receptor-like kinase 1 gene. Circ Res 112(1):113–127CrossRefPubMed Garrido-Martin EM et al (2013) Vascular injury triggers Kruppel-like factor 6 mobilization and cooperation with specificity protein 1 to promote endothelial activation through upregulation of the activin receptor-like kinase 1 gene. Circ Res 112(1):113–127CrossRefPubMed
15.
Zurück zum Zitat Botella LM et al (2002) Transcriptional activation of endoglin and transforming growth factor-beta signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury. Blood 100(12):4001–4010CrossRefPubMed Botella LM et al (2002) Transcriptional activation of endoglin and transforming growth factor-beta signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury. Blood 100(12):4001–4010CrossRefPubMed
16.
Zurück zum Zitat Shovlin CL et al (2000) Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 91(1):66–67CrossRefPubMed Shovlin CL et al (2000) Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 91(1):66–67CrossRefPubMed
17.
Zurück zum Zitat Plauchu H et al (1989) Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 32(3):291–297CrossRefPubMed Plauchu H et al (1989) Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 32(3):291–297CrossRefPubMed
18.
19.
Zurück zum Zitat Dupuis-Girod S, Cottin V, Shovlin CL (2017) The lung in hereditary hemorrhagic telangiectasia. Respiration 94(4):315–330CrossRefPubMed Dupuis-Girod S, Cottin V, Shovlin CL (2017) The lung in hereditary hemorrhagic telangiectasia. Respiration 94(4):315–330CrossRefPubMed
20.
Zurück zum Zitat Wirsching KEC, Haubner F, Kuhnel TS (2017) Influence of temporary nasal occlusion (tNO) on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia (HHT). Eur Arch Otorhinolaryngol 274(4):1891–1896CrossRefPubMed Wirsching KEC, Haubner F, Kuhnel TS (2017) Influence of temporary nasal occlusion (tNO) on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia (HHT). Eur Arch Otorhinolaryngol 274(4):1891–1896CrossRefPubMed
21.
Zurück zum Zitat Werner JA et al (1997) Treatment of recurrent epistaxis in Rendu-Osler-Weber disease. HNO 45(9):673–681CrossRefPubMed Werner JA et al (1997) Treatment of recurrent epistaxis in Rendu-Osler-Weber disease. HNO 45(9):673–681CrossRefPubMed
22.
Zurück zum Zitat Werner JA et al (1997) Nd:YAG laser therapy of recurrent epistaxis in hereditary hemorrhagic telangiectasia. Laryngorhinootologie 76(8):495–501CrossRefPubMed Werner JA et al (1997) Nd:YAG laser therapy of recurrent epistaxis in hereditary hemorrhagic telangiectasia. Laryngorhinootologie 76(8):495–501CrossRefPubMed
23.
Zurück zum Zitat Wirsching KEC, Kuhnel TS (2017) Update on clinical strategies in hereditary hemorrhagic telangiectasia from an ENT point of view. Clin Exp Otorhinolaryngol 10(2):153–157CrossRefPubMed Wirsching KEC, Kuhnel TS (2017) Update on clinical strategies in hereditary hemorrhagic telangiectasia from an ENT point of view. Clin Exp Otorhinolaryngol 10(2):153–157CrossRefPubMed
24.
Zurück zum Zitat Fernandez LA et al (2007) Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1/endoglin pathway in endothelial cells. Thromb Haemost 97(2):254–262CrossRef Fernandez LA et al (2007) Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1/endoglin pathway in endothelial cells. Thromb Haemost 97(2):254–262CrossRef
25.
Zurück zum Zitat Albinana V et al (2010) Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): effects of raloxifene, on endoglin and ALK1 expression in endothelial cells. Thromb Haemost 103(3):525–534CrossRefPubMed Albinana V et al (2010) Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): effects of raloxifene, on endoglin and ALK1 expression in endothelial cells. Thromb Haemost 103(3):525–534CrossRefPubMed
26.
Zurück zum Zitat Albinana V et al (2011) Immunosuppressor FK506 increases endoglin and activin receptor-like kinase 1 expression and modulates transforming growth factor-beta1 signaling in endothelial cells. Mol Pharmacol 79(5):833–843CrossRefPubMed Albinana V et al (2011) Immunosuppressor FK506 increases endoglin and activin receptor-like kinase 1 expression and modulates transforming growth factor-beta1 signaling in endothelial cells. Mol Pharmacol 79(5):833–843CrossRefPubMed
27.
Zurück zum Zitat Skaro AI, Marotta PJ, McAlister VC (2006) Regression of cutaneous and gastrointestinal telangiectasia with sirolimus and aspirin in a patient with hereditary hemorrhagic telangiectasia. Ann Intern Med 144(3):226–227CrossRefPubMed Skaro AI, Marotta PJ, McAlister VC (2006) Regression of cutaneous and gastrointestinal telangiectasia with sirolimus and aspirin in a patient with hereditary hemorrhagic telangiectasia. Ann Intern Med 144(3):226–227CrossRefPubMed
28.
Zurück zum Zitat Ruiz-Llorente L et al (2017) Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia. Expert Opin Ther Targets 21(10):933–947CrossRefPubMed Ruiz-Llorente L et al (2017) Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia. Expert Opin Ther Targets 21(10):933–947CrossRefPubMed
29.
Zurück zum Zitat Lopez-Novoa JM, Bernabeu C (2010) The physiological role of endoglin in the cardiovascular system. Am J Physiol Heart Circ Physiol 299(4):H959–74CrossRefPubMed Lopez-Novoa JM, Bernabeu C (2010) The physiological role of endoglin in the cardiovascular system. Am J Physiol Heart Circ Physiol 299(4):H959–74CrossRefPubMed
Metadaten
Titel
Diagnostik und Therapie des M. Osler
verfasst von
PD Dr. med. F. Haubner
Prof. Dr. T. Kühnel
Publikationsdatum
23.04.2018
Verlag
Springer Medizin
Erschienen in
HNO / Ausgabe 5/2018
Print ISSN: 0017-6192
Elektronische ISSN: 1433-0458
DOI
https://doi.org/10.1007/s00106-018-0503-8

Weitere Artikel der Ausgabe 5/2018

HNO 5/2018 Zur Ausgabe

Original article

Bothersome tinnitus

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.